Aldeyra Therapeutics, Inc.

ALDX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$7,688-$9,767-$9,930-$15,809
Dep. & Amort.$64$62$61$64
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$197$0$1,263
Change in WC-$1,761$1,332-$4,750$2,866
Other Non-Cash$2,365-$379$2,149-$421
Operating Cash Flow-$7,021-$8,555-$12,470-$12,037
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$24,554-$15,710-$21,564
Inv. Sales/Matur.$25,000$24,000$23,000$20,000
Other Inv. Act.$0$0$0$0
Investing Cash Flow$25,000-$554$7,290-$1,564
Financing Activities
Debt Repay.$0$0$0-$293
Stock Issued$121$0$1,003$300
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$121$0$1,003$8
Forex Effect$0$0$0$0
Net Chg. in Cash$18,099-$9,109-$4,176-$13,593
Supplemental Information
Beg. Cash$41,241$50,351$54,527$68,120
End Cash$59,341$41,241$50,351$54,527
Free Cash Flow-$7,021-$8,555-$12,470-$12,037